摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-fluoro-4-[1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine | 933785-38-7

中文名称
——
中文别名
——
英文名称
5-fluoro-4-[1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine
英文别名
5-Fluoro-4-[3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine
5-fluoro-4-[1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine化学式
CAS
933785-38-7
化学式
C12H14FN5O
mdl
——
分子量
263.274
InChiKey
ICBMSEIEDDMLMZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    78.8
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease
    申请人:Andersson Lars
    公开号:US20090105252A1
    公开(公告)日:2009-04-23
    Compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined in the specification as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    该专利涉及式I的化合物,其中R1,R2,R3,R4,R5,R6,R7,R8和R9如规范中所定义,作为基础物质或药物可接受的盐,溶剂或其盐的溶剂,以及制备它们的方法,其中使用了新的中间体,含有所述化合物的制药配方以及在治疗中使用所述化合物的用途。
  • NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE
    申请人:AstraZeneca AB
    公开号:EP1945628A1
    公开(公告)日:2008-07-23
  • [EN] NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] NOUVEAUX DERIVES DE PYRIMIDINE ET LEUR UTILISATION EN THERAPIE ET POUR LA PRODUCTION D'UN MEDICAMENT POUR LA PREVENTION ET/OU LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
    申请人:ASTRAZENECA AB
    公开号:WO2007040440A1
    公开(公告)日:2007-04-12
    [EN] The present invention relates to use of compounds of formula (I) as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, as pharmaceutical ingredients for treatment of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and/or dementia pugilistica .
    [FR] L'invention concerne l'utilisation de composés de formule (I) en tant que base libre ou un sel, solvate ou solvate d'un sel acceptable sur le plan pharmaceutique de ceux-ci. L'invention concerne également un procédé de préparation desdits composés et des nouveaux intermédiaires utilisés dans ce procédé. Lesdits composés sont utilisés en tant qu'ingrédients pharmaceutiques pour le traitement des maladies suivantes : démences, maladie d'Alzheimer, maladie de Parkinson, démences frontotemporales de type Parkinson, Parkinson démence île de Guam, démence associée au VIH, maladies à enchevêtrement neurofibrillaire associé et/ou démence pugilistique.
查看更多